Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in Advanced Urothelial Carcinoma
NCT07185945Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of zanzalintinib in urothelial carcinoma (UC). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zanzalintinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07185945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185945.